- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Ocular gene therapy is an emerging area for the treatment of inherited retinal diseases. The surgical considerations for this novel approach to treatment will be presented.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1.00 hours of participation for continuing education for allied health professionals.
- Community Eye Care Professionals
- Medical students
- Graduate students
- Postdoctoral Fellows
- Vision Scientists
At the end of this session, I will be able to:
- To understand the indications for ocular gene therapy
- To learn that surgical considerations for subretinal gene therapy
- To demonstrate intraoperative optical coherence tomography findings during subretinal gene therapy
William J. Wirostko, MD
Professor of Ophthalmology & Visual Sciences
Medical College of Wisconsin
Andreas K. Lauer, MD
Professor and Thiele-Petti Chair of Ophthalmology
Casey Eye Institute-Oregon Health & Science University
All persons in control of content has no relevant financial relationships to disclose with the exception of:
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
|Andreas Lauer, MD||NIH/NEI||Principal Investigator|